# A Study in Prevention of Re-emergence of Depression Symptoms

> **NCT01299272** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 1249 (actual)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** LY2216684
- **DRUG:** Placebo
- **DRUG:** SSRI

## Key facts

- **NCT ID:** NCT01299272
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05
- **Primary completion:** 2013-11
- **Final completion:** 2013-11
- **Target enrollment:** 1249 (ACTUAL)
- **Last updated:** 2018-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01299272

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01299272, "A Study in Prevention of Re-emergence of Depression Symptoms". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01299272. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*